Adial Pharmaceuticals (ADIL) Competitors $0.38 +0.01 (+2.62%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. RENB, TENX, DARE, CVKD, KZR, LEXX, RNTX, XCUR, HOTH, and MIRAShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Lunai Bioworks (RENB), Tenax Therapeutics (TENX), Dare Bioscience (DARE), Cadrenal Therapeutics (CVKD), Kezar Life Sciences (KZR), Lexaria Bioscience (LEXX), Rein Therapeutics (RNTX), Exicure (XCUR), Hoth Therapeutics (HOTH), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Lunai Bioworks Tenax Therapeutics Dare Bioscience Cadrenal Therapeutics Kezar Life Sciences Lexaria Bioscience Rein Therapeutics Exicure Hoth Therapeutics MIRA Pharmaceuticals Adial Pharmaceuticals (NASDAQ:ADIL) and Lunai Bioworks (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Does the media favor ADIL or RENB? In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Adial Pharmaceuticals and 5 mentions for Lunai Bioworks. Adial Pharmaceuticals' average media sentiment score of 0.55 beat Lunai Bioworks' score of 0.19 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lunai Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ADIL or RENB? Adial Pharmaceuticals presently has a consensus price target of $4.75, indicating a potential upside of 1,150.00%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Adial Pharmaceuticals is more favorable than Lunai Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Lunai Bioworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of ADIL or RENB? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 4.3% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ADIL or RENB? Adial Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Is ADIL or RENB more profitable? Lunai Bioworks' return on equity of -60.38% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -191.31% -153.59% Lunai Bioworks N/A -60.38%-47.04% Which has higher earnings and valuation, ADIL or RENB? Lunai Bioworks is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$13.20M-$1.05-0.36Lunai BioworksN/AN/A-$88.43M-$0.77-2.00 SummaryAdial Pharmaceuticals beats Lunai Bioworks on 10 of the 14 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30M$233.52M$6.01B$10.54BDividend YieldN/A3.80%5.92%4.70%P/E Ratio-0.3631.8176.7726.37Price / SalesN/A5,631.43583.98127.43Price / CashN/A13.1938.1961.33Price / Book0.59109.0512.516.41Net Income-$13.20M-$90.99M$3.30B$277.11M7 Day Performance13.53%1.52%28,039.44%1.07%1 Month Performance0.88%5.82%30,444.22%7.43%1 Year Performance-60.02%568.28%35,707.86%35.04% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.2077 of 5 stars$0.38+2.6%$4.75+1,150.0%-62.0%$8.30MN/A-0.3620News CoverageAnalyst UpgradeGap UpRENBLunai Bioworks0.5337 of 5 stars$0.17+5.6%N/A-66.6%$29.71MN/A-0.2220Stock SplitGap DownHigh Trading VolumeTENXTenax Therapeutics2.5798 of 5 stars$6.50-0.5%$18.00+176.9%+124.1%$29.66MN/A-7.079Positive NewsDAREDare Bioscience1.6756 of 5 stars$2.14+3.9%$10.00+367.3%-33.0%$28.85M-$17.70K-1.0030CVKDCadrenal Therapeutics2.5364 of 5 stars$13.78+0.7%$32.00+132.2%+9.1%$28.21MN/A-1.554KZRKezar Life Sciences4.0464 of 5 stars$3.80-2.3%$9.00+136.8%-50.1%$27.82M$7M-0.3960Positive NewsHigh Trading VolumeLEXXLexaria Bioscience3.3075 of 5 stars$1.42+8.4%$4.00+181.7%-69.1%$27.78M$460K-2.127RNTXRein Therapeutics3.2816 of 5 stars$1.19+6.3%$10.00+740.3%N/A$27.74MN/A-0.449Gap UpHigh Trading VolumeXCURExicure1.9709 of 5 stars$4.25+21.1%N/A+32.7%$26.86M$500K-1.1050Gap UpHOTHHoth Therapeutics1.9681 of 5 stars$1.95-5.8%$4.00+105.1%+86.0%$25.86MN/A-1.824Short Interest ↑MIRAMIRA Pharmaceuticals0.8097 of 5 stars$1.35+3.8%$17.00+1,159.3%+10.9%$25.74MN/A-2.762 Related Companies and Tools Related Companies Lunai Bioworks Alternatives Tenax Therapeutics Alternatives Dare Bioscience Alternatives Cadrenal Therapeutics Alternatives Kezar Life Sciences Alternatives Lexaria Bioscience Alternatives Rein Therapeutics Alternatives Exicure Alternatives Hoth Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierThis innovative drone developer has been selected to supply its Flex FPV Modular Drones to the U.S. Army. T...The Tomorrow Investor | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADIL Stock Alerts